Is Organogenesis Holdings Inc. (ORGO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 22.9% / 30% | 26.1% / 30% | 60.6% / 30% | 0.41% / 5% | ✗ NOT HALAL |
| DJIM | 22.9% / 33% | 26.1% / 33% | 60.6% / 33% | 0.41% / 5% | ✗ NOT HALAL |
| MSCI | 13.7% / 33% | 15.6% / 33% | 36.3% / 33% | 0.41% / 5% | ✗ NOT HALAL |
| S&P | 22.9% / 33% | 26.1% / 33% | 60.6% / 33% | 0.41% / 5% | ✗ NOT HALAL |
| FTSE | 13.7% / 33% | 15.6% / 33% | 36.3% / 50% | 0.41% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 75.6% | |
| Operating Margin | 28.9% | |
| Net Margin | 6.6% | |
| Return on Equity (ROE) | 9.0% | |
| Return on Assets (ROA) | 6.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$10M |
| Free Cash Flow | -$24M |
| Total Debt | $82M |
| Debt-to-Equity | 18.9 |
| Current Ratio | 3.6 |
| Total Assets | $599M |
Price & Trading
| Last Close | $2.42 |
| 50-Day MA | $3.37 |
| 200-Day MA | $4.29 |
| Avg Volume | 763K |
| Beta | 1.4 |
|
52-Week Range
$2.28
| |
About Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Organogenesis Holdings Inc. (ORGO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Organogenesis Holdings Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Organogenesis Holdings Inc.'s debt ratio?
Organogenesis Holdings Inc.'s debt ratio is 22.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.7%.
What are Organogenesis Holdings Inc.'s key financial metrics?
Organogenesis Holdings Inc. has a market capitalization of $295M, trailing P/E ratio of 15.3, and revenue of $563M. The company maintains a gross margin of 75.6% and a net margin of 6.6%. Return on equity stands at 9.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.